Eli Lilly and Company $LLY Stake Lifted by 1858 Wealth Management LLC

1858 Wealth Management LLC increased its stake in Eli Lilly and Company (NYSE:LLY) by 9.3% in the 2nd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 1,397 shares of the company’s stock after acquiring an additional 119 shares during the period. 1858 Wealth Management LLC’s holdings in Eli Lilly and Company were worth $1,089,000 at the end of the most recent reporting period.

Several other institutional investors and hedge funds have also made changes to their positions in LLY. Brighton Jones LLC boosted its holdings in shares of Eli Lilly and Company by 22.0% in the fourth quarter. Brighton Jones LLC now owns 9,597 shares of the company’s stock valued at $7,409,000 after acquiring an additional 1,730 shares in the last quarter. Revolve Wealth Partners LLC lifted its stake in Eli Lilly and Company by 2.8% during the fourth quarter. Revolve Wealth Partners LLC now owns 1,471 shares of the company’s stock valued at $1,136,000 after purchasing an additional 40 shares during the last quarter. Covestor Ltd lifted its stake in Eli Lilly and Company by 24.9% during the first quarter. Covestor Ltd now owns 426 shares of the company’s stock valued at $352,000 after purchasing an additional 85 shares during the last quarter. GAMMA Investing LLC lifted its stake in Eli Lilly and Company by 25.8% during the first quarter. GAMMA Investing LLC now owns 18,000 shares of the company’s stock valued at $14,866,000 after purchasing an additional 3,696 shares during the last quarter. Finally, Warner Financial Inc. lifted its stake in Eli Lilly and Company by 129.2% during the first quarter. Warner Financial Inc. now owns 1,123 shares of the company’s stock valued at $927,000 after purchasing an additional 633 shares during the last quarter. 82.53% of the stock is currently owned by institutional investors.

Insider Buying and Selling

In related news, Director Gabrielle Sulzberger bought 117 shares of the business’s stock in a transaction on Tuesday, August 12th. The stock was bought at an average price of $641.18 per share, for a total transaction of $75,018.06. Following the transaction, the director directly owned 2,703 shares in the company, valued at $1,733,109.54. This represents a 4.52% increase in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. Also, Director J Erik Fyrwald bought 1,565 shares of the business’s stock in a transaction on Tuesday, August 12th. The stock was bought at an average price of $642.33 per share, with a total value of $1,005,246.45. Following the transaction, the director owned 74,578 shares in the company, valued at approximately $47,903,686.74. This represents a 2.14% increase in their ownership of the stock. The disclosure for this purchase can be found here. Over the last quarter, insiders have bought 4,514 shares of company stock worth $2,894,841. Insiders own 0.13% of the company’s stock.

Eli Lilly and Company Stock Down 2.6%

Shares of NYSE:LLY opened at $833.08 on Friday. The company has a debt-to-equity ratio of 1.86, a quick ratio of 1.00 and a current ratio of 1.28. The company has a market cap of $788.47 billion, a PE ratio of 54.45, a price-to-earnings-growth ratio of 1.16 and a beta of 0.47. Eli Lilly and Company has a 52 week low of $623.78 and a 52 week high of $937.00. The firm has a 50 day simple moving average of $742.42 and a 200 day simple moving average of $765.94.

Eli Lilly and Company (NYSE:LLY) last issued its quarterly earnings results on Thursday, August 7th. The company reported $6.31 EPS for the quarter, beating the consensus estimate of $5.59 by $0.72. The business had revenue of $15.56 billion during the quarter, compared to the consensus estimate of $14.40 billion. Eli Lilly and Company had a net margin of 25.91% and a return on equity of 92.72%. The firm’s quarterly revenue was up 37.6% on a year-over-year basis. During the same quarter in the prior year, the firm earned $3.92 EPS. Eli Lilly and Company has set its FY 2025 guidance at 21.750-23.000 EPS. As a group, research analysts expect that Eli Lilly and Company will post 23.48 earnings per share for the current year.

Analyst Ratings Changes

Several research firms recently commented on LLY. DZ Bank raised shares of Eli Lilly and Company from a “hold” rating to a “strong-buy” rating in a research note on Thursday, August 14th. Morgan Stanley cut their target price on shares of Eli Lilly and Company from $1,028.00 to $1,023.00 and set an “overweight” rating for the company in a research note on Friday, October 3rd. HSBC increased their target price on shares of Eli Lilly and Company from $700.00 to $800.00 in a research note on Wednesday, October 1st. Daiwa Capital Markets lowered shares of Eli Lilly and Company from an “outperform” rating to a “neutral” rating and set a $700.00 target price for the company. in a research note on Sunday, August 17th. Finally, Hsbc Global Res upgraded shares of Eli Lilly and Company from a “moderate sell” rating to a “hold” rating in a research report on Wednesday, August 27th. One research analyst has rated the stock with a Strong Buy rating, fourteen have assigned a Buy rating and ten have assigned a Hold rating to the company’s stock. According to MarketBeat, the stock has a consensus rating of “Moderate Buy” and an average price target of $948.56.

Eli Lilly and Company Company Profile

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.